Corcept Therapeutics Incorporated (CORT)
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
$111.62-1.05%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - PharmaceuticalsSnapshot 2026-09-04
QuarterlyIQ Insights · CORT
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 830.8 | 761.4 | 675.0 | 482.4 | 401.9 | 366.0 | 353.9 | 306.5 | 251.2 | 159.2 | 81.3 | 50.3 | 26.6 | 10.4 | 3.3 | 0.0 |
| Total Revenues | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 |
| Cost of Revenues | 14.1 | 13.0 | 10.9 | 6.5 | 5.4 | 5.3 | 5.6 | 5.5 | 5.2 | — | — | 1.4 | 0.9 | 0.1 | 0.1 | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 556.5 | 448.7 | 280.3 | 184.3 | 152.8 | 122.4 | 105.3 | 100.4 | 81.3 | 62.4 | 45.2 | 36.9 | 34.9 | 31.2 | 25.4 | — |
| R&D Expenses | 253.9 | 254.9 | 246.9 | 184.4 | 131.0 | 113.9 | 114.8 | 89.0 | 75.2 | 40.4 | 23.8 | 15.4 | 18.4 | 20.5 | 14.1 | 21.0 |
| Operating Income | 6.4 | 44.8 | 137.0 | 107.3 | 112.6 | 124.5 | 128.2 | 111.6 | 89.5 | 52.9 | 10.2 | (3.4) | (27.6) | (41.5) | (36.3) | (32.3) |
| Earnings from Continuing Operations | ||||||||||||||||
| Other Non-Operating Income / Expenses | 20.0 | 21.7 | 24.5 | 17.3 | 3.6 | 0.5 | — | — | — | — | — | — | — | — | — | — |
| EBT, Incl. Unusual Items | 26.4 | 66.5 | 161.5 | 124.6 | 116.2 | 125.0 | 131.6 | 116.7 | 92.2 | 52.8 | — | — | — | — | — | — |
| Income Tax Expense | (28.8) | (33.2) | 20.3 | 18.4 | 14.8 | 12.5 | 25.6 | 22.5 | 16.7 | (76.3) | 0.0 | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | 55.2 | 99.7 | 141.2 | 106.1 | 101.4 | 112.5 | 106.0 | 94.2 | 75.4 | 129.1 | 8.1 | (6.4) | (31.4) | (46.0) | (38.0) | (32.4) |
| Per Share | ||||||||||||||||
| Basic EPS | 0.52 | 0.95 | 1.35 | 1.02 | 0.95 | 0.97 | 0.92 | 0.82 | 0.65 | 1.14 | — | — | — | — | — | — |
| Diluted EPS | 0.47 | 0.82 | 1.23 | 0.94 | 0.87 | 0.89 | 0.85 | 0.77 | 0.60 | 1.04 | — | — | — | — | — | — |
| Revenue per Share | 7.02 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Dividend per Share | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.00 | — | — |
| Basic Weighted Avg Shares | 105.4 | 103.9 | 103.2 | 103.6 | 106.8 | 115.7 | 115.4 | 114.3 | 115.3 | 113.5 | 110.6 | — | — | — | — | — |
| Diluted Weighted Avg Shares | 118.4 | 120.0 | 113.5 | 111.7 | 116.0 | 126.0 | 124.2 | 122.6 | 126.7 | 124.5 | 116.1 | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | 45.9 | 137.7 | 108.3 | 113.9 | 125.5 | 128.7 | 112.3 | 89.7 | 53.0 | 10.3 | (3.3) | (27.5) | (41.4) | (36.2) | (32.3) |
| EBIT | 6.4 | 44.8 | 137.0 | 107.3 | 112.6 | 124.5 | 128.2 | 111.6 | 89.5 | 52.9 | 10.2 | (3.4) | (27.6) | (41.5) | (36.3) | (32.3) |
| Effective Tax Rate | -109.3% | — | — | 14.8% | 12.7% | 10.0% | 19.4% | 19.3% | 18.2% | -144.5% | — | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.